The immune plasticity of mesenchymal stromal cells from mice and men: Concordances and discrepancies

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 3, 2012, Pages 824-837

  Romieu Mourez, Raphaelle ^a   Coutu, Daniel L ^a   Galipeau, Jacques ^b  

^a MCGILL UNIVERSITY   (Canada)

^b EMORY UNIVERSITY   (United States)

Author keywords

Human; Immune suppression; Mouse; MSCs; Review

Indexed keywords

ABATACEPT; CD20 ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GALECTIN 1; GALECTIN 3; GAMMA INTERFERON; GLUCOCORTICOID; GREEN FLUORESCENT PROTEIN; HLA G ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ANIMAL CELL CULTURE; ANTIGEN PRESENTATION; ARTICLE; BONE MARROW BIOPSY; CANCER CELL CULTURE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; CELL DIFFERENTIATION; CELL ISOLATION; CHRONIC GRAFT VERSUS HOST DISEASE; CROSS PRESENTATION; FIBROBLAST; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL CULTURE; HUMAN VERSUS ANIMAL COMPARISON; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MESENCHYMAL STROMA CELL; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPIC PLASTICITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; SPECIES DIFFERENCE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; ANIMAL; IMMUNOLOGY; INFLAMMATION; MOUSE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALIA; MURINAE; MUS; RODENTIA;

ANIMALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MESENCHYMAL STROMAL CELLS; MICE; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY;

EID: 84860849630     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (93)

1. R. E. Newman, D. Yoo, M. A. LeRoux, A. Danilkovitch-Miagkova. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets, 8(2), 110-23 (2009)
2. J. Mestas, C. C. Hughes. Of mice and not men: differences between mouse and human immunology. J Immunol, 172(5), 2731-8 (2004) (Pubitemid 38263654)
3. S. A. Wexler, C. Donaldson, P. Denning-Kendall, C. Rice, B. Bradley, J. M. Hows. Adult bone marrow is a rich source of human mesenchymal 'stem' cells but umbilical cord and mobilized adult blood are not. Br J Haematol, 121(2), 368-74 (2003) (Pubitemid 36560606)
4. M. L. Weiss, C. Anderson, S. Medicetty, K. B. Seshareddy, R. J. Weiss, I. VanderWerff, D. Troyer, K. R. McIntosh. Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells, 26(11), 2865-74 (2008)
5. P. S. Cho, D. J. Messina, E. L. Hirsh, N. Chi, S. N. Goldman, D. P. Lo, I. R. Harris, S. H. Popma, D. H. Sachs, C. A. Huang. Immunogenicity of umbilical cord tissue derived cells. Blood, 111(1), 430-8 (2008)
6. L. Sun, D. Wang, J. Liang, H. Zhang, X. Feng, H. Wang, B. Hua, B. Liu, S. Ye, X. Hu, W. Xu, X. Zeng, Y. Hou, G. S. Gilkeson, R. M. Silver, L. Lu, S. Shi. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum, 62(8), 2467-75 (2010)
7. S. Garcia, A. Bernad, M. C. Martin, J. C. Cigudosa, J. Garcia-Castro, R. de La Fuente. Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. Exp Cell Res, 316(9), 1648-50 (2010)
8. A. Torsvik, G. V. Rosland, A. Svendsen, A. Molven, H. Immervoll, E. McCormack, P. E. Lonning, M. Primon, E. Sobala, J. C. Tonn, R. Goldbrunner, C. Schichor, J. Mysliwietz, T. T. Lah, H. Motaln, S. Knappskog, R. Bjerkvig. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track -letter. Cancer Res, 70(15), 6393-6 (2010)
9. D. G. Phinney, G. Kopen, R. L. Isaacson, D. J. Prockop. Plastic adherent stromal cells from the bone marrow of commonly used strains of inbred mice: variations in yield, growth, and differentiation. J Cell Biochem, 72(4), 570-85 (1999) (Pubitemid 29088308)
10. S. A. Kuznetsov, A. J. Friedenstein, P. G. Robey. Factors required for bone marrow stromal fibroblast colony formation in vitro. Br J Haematol, 97(3), 561-70 (1997) (Pubitemid 27261620)
11. M. A. Haniffa, X. N. Wang, U. Holtick, M. Rae, J. D. Isaacs, A. M. Dickinson, C. M. Hilkens, M. P. Collin. Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol, 179(3), 1595-604 (2007)
12. W. Wagner, F. Wein, A. Seckinger, M. Frankhauser, U. Wirkner, U. Krause, J. Blake, C. Schwager, V. Eckstein, W. Ansorge, A. D. Ho. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol, 33(11), 1402-16 (2005) (Pubitemid 41541969)
13. D. Campioni, S. Moretti, L. Ferrari, M. Punturieri, G. L. Castoldi, F. Lanza. Immunophenotypic heterogeneity of bone marrow-derived mesenchymal stromal cells from patients with hematologic disorders: correlation with bone marrow microenvironment. Haematologica, 91(3), 364-8 (2006)
14. S. Cappellesso-Fleury, B. Puissant-Lubrano, P. A. Apoil, M. Titeux, P. Winterton, L. Casteilla, P. Bourin, A. Blancher. Human fibroblasts share immunosuppressive properties with bone marrow mesenchymal stem cells. J Clin Immunol, 30(4), 607-19 (2010)
15. W. S. Lee, Y. Suzuki, S. S. Graves, M. Iwata, G. M. Venkataraman, M. Mielcarek, L. J. Peterson, S. Ikehara, B. Torok-Storb, R. Storb. Canine Bone Marrow Derived Mesenchymal Stromal Cells Suppress Allo-Reactive Lymphocyte Proliferation in vitro but Fail to Enhance Engraftment in Canine Bone Marrow Transplantation. Biol Blood Marrow Transplant (2010)
16. F. Wang, T. Yasuhara, T. Shingo, M. Kameda, N. Tajiri, W. J. Yuan, A. Kondo, T. Kadota, T. Baba, J. T. Tayra, Y. Kikuchi, Y. Miyoshi, I. Date. Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1alpha. BMC Neurosci, 11(52 (2010)
17. L. Chen, E. E. Tredget, C. Liu, Y. Wu. Analysis of allogenicity of mesenchymal stem cells in engraftment and wound healing in mice. PLoS One, 4(9), e7119 (2009)
18. M. A. Gonzalez, E. Gonzalez-Rey, L. Rico, D. Buscher, M. Delgado. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum, 60(4), 1006-19 (2009)
19. R. Romieu-Mourez, M. Francois, A. Abate, M. N. Boivin, E. Birman, D. Bailey, J. L. Bramson, K. Forner, Y. K. Young, J. A. Medin, J. Galipeau. Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-{gamma} and tumor necrosis factor-{alpha} priming. Cancer Res, 70(20), 7742-7 (2010)
20. F. Morandi, L. Raffaghello, G. Bianchi, F. Meloni, A. Salis, E. Millo, S. Ferrone, V. Barnaba, V. Pistoia. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-Associated antigens. Stem Cells, 26(5), 1275-87 (2008)
21. M. Francois, R. Romieu-Mourez, S. Stock-Martineau, M. N. Boivin, J. L. Bramson, J. Galipeau. Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood, 114(13), 2632-8 (2009)
22. J. Stagg, S. Pommey, N. Eliopoulos, J. Galipeau. Interferon-gamma- stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood, 107(6), 2570-7 (2006) (Pubitemid 43348704)
23. G. Ren, L. Zhang, X. Zhao, G. Xu, Y. Zhang, A. I. Roberts, R. C. Zhao, Y. Shi. Mesenchymal stem cellmediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2(2), 141-50 (2008) (Pubitemid 351181031)
24. S. Ghannam, J. Pene, G. Torcy-Moquet, C. Jorgensen, H. Yssel. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol, 185(1), 302-12 (2010)
25. R. Romieu-Mourez, M. Francois, M. N. Boivin, M. Bouchentouf, D. E. Spaner, J. Galipeau. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol, 182(12), 7963-73 (2009)
26. M. Meiron, Y. Zohar, R. Anunu, G. Wildbaum, N. Karin. CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells. J Exp Med, 205(11), 2643-55 (2008)
27. L. Raffaghello, G. Bianchi, M. Bertolotto, F. Montecucco, A. Busca, F. Dallegri, L. Ottonello, V. Pistoia. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells, 26(1), 151-62 (2008)
28. A. J. Nauta, A. B. Kruisselbrink, E. Lurvink, R. Willemze, W. E. Fibbe. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol, 177(4), 2080-7 (2006) (Pubitemid 44200965)
29. P. A. Sotiropoulou, S. A. Perez, A. D. Gritzapis, C. N. Baxevanis, M. Papamichail. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells, 24(1), 74-85 (2006)
30. S. A. Patel, J. R. Meyer, S. J. Greco, K. E. Corcoran, M. Bryan, P. Rameshwar. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol, 184(10), 5885-94 (2010)
31. J. Stagg, U. Divisekera, N. McLaughlin, J. Sharkey, S. Pommey, D. Denoyer, K. M. Dwyer, M. J. Smyth. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A, 107(4), 1547-52 (2010)
32. M. Rafei, P. M. Campeau, A. Aguilar-Mahecha, M. Buchanan, P. Williams, E. Birman, S. Yuan, Y. K. Young, M. N. Boivin, K. Forner, M. Basik, J. Galipeau. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol, 182(10), 5994-6002 (2009)
33. L. A. Ortiz, M. Dutreil, C. Fattman, A. C. Pandey, G. Torres, K. Go, D. G. Phinney. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A, 104(26), 11002-7 (2007)
34. A. Nasef, C. Mazurier, S. Bouchet, S. Francois, A. Chapel, D. Thierry, N. C. Gorin, L. Fouillard. Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression. Cell Immunol, 253(1-2), 16-22 (2008)
35. A. Nasef, N. Mathieu, A. Chapel, J. Frick, S. Francois, C. Mazurier, A. Boutarfa, S. Bouchet, N. C. Gorin, D. Thierry, L. Fouillard. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation, 84(2), 231-7 (2007) (Pubitemid 47205757)
36. Z. Selmani, A. Naji, I. Zidi, B. Favier, E. Gaiffe, L. Obert, C. Borg, P. Saas, P. Tiberghien, N. Rouas-Freiss, E. D. Carosella, F. Deschaseaux. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells, 26(1), 212-22 (2008)
37. M. Sioud, A. Mobergslien, A. Boudabous, Y. Floisand. Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scand J Immunol, 71(4), 267-74 (2010)
38. M. Najar, G. Raicevic, H. Id Boufker, B. Stamatopoulos, C. De Bruyn, N. Meuleman, D. Bron, M. Toungouz, L. Lagneaux. Modulated expression of adhesion molecules and galectin-1: role during mesenchymal stromal cell immunoregulatory functions. Exp Hematol, 38(10), 922-32 (2010)
39. F. Gieseke, J. Bohringer, R. Bussolari, M. Dominici, R. Handgretinger, I. Muller. Human multipotent mesenchymal stromal cells employ galectin-1 to inhibit immune effector cells. Blood (2010)
40. K. O'Donoghue, J. Chan, J. de La Fuente, N. Kennea, A. Sandison, J. R. Anderson, I. A. Roberts, N. M. Fisk. Microchimerism in female bone marrow and bone decades after fetal mesenchymal stem-cell trafficking in pregnancy. Lancet, 364(9429), 179-82 (2004) (Pubitemid 38891690)
41. K. J. Beggs, A. Lyubimov, J. N. Borneman, A. Bartholomew, A. Moseley, R. Dodds, M. P. Archambault, A. K. Smith, K. R. McIntosh. Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons. Cell Transplant, 15(8-9), 711-21 (2006) (Pubitemid 46095254)
42. N. Eliopoulos, J. Stagg, L. Lejeune, S. Pommey, J. Galipeau. Allogeneic marrow stromal cells are immune rejected by MHC class I-And class II-mismatched recipient mice. Blood, 106(13), 4057-65 (2005) (Pubitemid 41775910)
43. A. J. Poncelet, J. Vercruysse, A. Saliez, P. Gianello. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation, 83(6), 783-90 (2007) (Pubitemid 46569198)
44. P. Renner, E. Eggenhofer, A. Rosenauer, F. C. Popp, J. F. Steinmann, P. Slowik, E. K. Geissler, P. Piso, H. J. Schlitt, M. H. Dahlke. Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function. Transplant Proc, 41(6), 2607-11 (2009)
45. M. Najar, R. Rouas, G. Raicevic, H. I. Boufker, P. Lewalle, N. Meuleman, D. Bron, M. Toungouz, P. Martiat, L. Lagneaux. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy, 11(5), 570-83 (2009)
46. I. Rasmusson, K. Le Blanc, B. Sundberg, O. Ringden. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol, 65(4), 336-43 (2007) (Pubitemid 46481102)
47. O. DelaRosa, E. Lombardo. Modulation of adult mesenchymal stem cells activity by toll-like receptors: implications on therapeutic potential. Mediators Inflamm, 2010(865601 (2010)
48. G. Ren, X. Zhao, L. Zhang, J. Zhang, A. L'Huillier, W. Ling, A. I. Roberts, A. D. Le, S. Shi, C. Shao, Y. Shi. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol, 184(5), 2321-8 (2010)
49. G. Ren, J. Su, L. Zhang, X. Zhao, W. Ling, A. L'Huillie, J. Zhang, Y. Lu, A. I. Roberts, W. Ji, H. Zhang, A. B. Rabson, Y. Shi. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells, 27(8), 1954-62 (2009)
50. K. Le Blanc, C. Tammik, K. Rosendahl, E. Zetterberg, O. Ringden. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol, 31(10), 890-6 (2003) (Pubitemid 37211373)
51. R. Romieu-Mourez, M. Francois, M. N. Boivin, J. Stagg, J. Galipeau. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. J Immunol, 179(3), 1549-58 (2007)
52. J. L. Chan, K. C. Tang, A. P. Patel, L. M. Bonilla, N. Pierobon, N. M. Ponzio, P. Rameshwar. Antigenpresenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood, 107(12), 4817-24 (2006) (Pubitemid 43882633)
53. D. Polchert, J. Sobinsky, G. Douglas, M. Kidd, A. Moadsiri, E. Reina, K. Genrich, S. Mehrotra, S. Setty, B. Smith, A. Bartholomew. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol, 38(6), 1745-55 (2008)
54. K. Nemeth, A. Leelahavanichkul, P. S. Yuen, B. Mayer, A. Parmelee, K. Doi, P. G. Robey, K. Leelahavanichkul, B. H. Koller, J. M. Brown, X. Hu, I. Jelinek, R. A. Star, E. Mezey. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med, 15(1), 42-9 (2009)
55. M. Najar, G. Raicevic, H. I. Boufker, H. F. Kazan, C. De Bruyn, N. Meuleman, D. Bron, M. Toungouz, L. Lagneaux. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol, 264(2), 171-9 (2010)
56. C. M. Hilkens, H. Vermeulen, R. J. van Neerven, F. G. Snijdewint, E. A. Wierenga, M. L. Kapsenberg. Differential modulation of T helper type 1 (Th1) and T helper type 2 (Th2) cytokine secretion by prostaglandin E2 critically depends on interleukin-2. Eur J Immunol, 25(1), 59-63 (1995)
57. C. Yao, D. Sakata, Y. Esaki, Y. Li, T. Matsuoka, K. Kuroiwa, Y. Sugimoto, S. Narumiya. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med, 15(6), 633-40 (2009)
58. C. Chizzolini, R. Chicheportiche, M. Alvarez, C. de Rham, P. Roux-Lombard, S. Ferrari-Lacraz, J. M. Dayer. Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood, 112(9), 3696-703 (2008)
59. A. F. Sheibanie, J. H. Yen, T. Khayrullina, F. Emig, M. Zhang, R. Tuma, D. Ganea. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23-IL-17 axis. J Immunol, 178(12), 8138-47 (2007) (Pubitemid 46898086)
60. S. Aggarwal, M. F. Pittenger. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105(4), 1815-22 (2005) (Pubitemid 40223708)
61. J. Maggini, G. Mirkin, I. Bognanni, J. Holmberg, I. M. Piazzon, I. Nepomnaschy, H. Costa, C. Canones, S. Raiden, M. Vermeulen, J. R. Geffner. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One, 5(2), e9252 (2010)
62. I. Rasmusson, O. Ringden, B. Sundberg, K. Le Blanc. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res, 305(1), 33-41 (2005) (Pubitemid 40380651)
63. K. Sato, K. Ozaki, I. Oh, A. Meguro, K. Hatanaka, T. Nagai, K. Muroi, K. Ozawa. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood, 109(1), 228-34 (2007) (Pubitemid 46053063)
64. R. Meisel, A. Zibert, M. Laryea, U. Gobel, W. Daubener, D. Dilloo. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood, 103(12), 4619-21 (2004) (Pubitemid 38745993)
65. J. Plumas, L. Chaperot, M. J. Richard, J. P. Molens, J. C. Bensa, M. C. Favrot. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia, 19(9), 1597-604 (2005) (Pubitemid 43090404)
66. M. Krampera, L. Cosmi, R. Angeli, A. Pasini, F. Liotta, A. Andreini, V. Santarlasci, B. Mazzinghi, G. Pizzolo, F. Vinante, P. Romagnani, E. Maggi, S. Romagnani, F. Annunziato. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 24(2), 386-98 (2006) (Pubitemid 44464808)
67. F. Gieseke, B. Schutt, S. Viebahn, E. Koscielniak, W. Friedrich, R. Handgretinger, I. Muller. Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression. Blood, 110(6), 2197-200 (2007) (Pubitemid 47443941)
68. J. M. Ryan, F. Barry, J. M. Murphy, B. P. Mahon. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol, 149(2), 353-63 (2007) (Pubitemid 47063057)
69. R. Meisel, S. Brockers, K. Heseler, O. Degistirici, H. Bulle, C. Woite, S. Stuhlsatz, W. Schwippert, M. Jager, R. Sorg, R. Henschler, J. Seissler, D. Dilloo, W. Daubener. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia (2011)
70. J. B. Weinberg. Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Mol Med, 4(9), 557-91 (1998) (Pubitemid 28523111)
71. W. Ge, J. Jiang, J. Arp, W. Liu, B. Garcia, H. Wang. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation, 90(12), 1312-20)
72. A. Augello, R. Tasso, S. M. Negrini, A. Amateis, F. Indiveri, R. Cancedda, G. Pennesi. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol, 35(5), 1482-90 (2005) (Pubitemid 40691430)
73. K. Le Blanc, I. Rasmusson, B. Sundberg, C. Gotherstrom, M. Hassan, M. Uzunel, O. Ringden. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, 363(9419), 1439-41 (2004) (Pubitemid 38586721)
74. K. Le Blanc, F. Frassoni, L. Ball, F. Locatelli, H. Roelofs, I. Lewis, E. Lanino, B. Sundberg, M. E. Bernardo, M. Remberger, G. Dini, R. M. Egeler, A. Bacigalupo, W. Fibbe, O. Ringden. Mesenchymal stem cells for treatment of steroidresistant, severe, acute graft-versus-host disease: a phase II study. Lancet, 371(9624), 1579-86 (2008) (Pubitemid 351626841)
75. P. J. Martin, J. P. Uberti, R. J. Soiffer, H. Klingemann, E. K. Waller, A. S. Daly, R. P. Herrmann, P. Kebriaei. Prochymal® Improves Response Rates in Patients with Steroid-Refractory Acute Graft versus Host Disease (SRGVHD) Involving the Liver and Gut: Results of a Randomized, Placebo-controlled, Multicenter Phase III trial in GVHD. BMT Tandem Meetings (Abstract) (2010)
76. P. Szabolcs, G. Visani, F. Locatelli, G. Kleiner, J. A. Talano, E. Nemecek, J. Kurtzberg. Treatment of steroidrefractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; Results of the pediatric subset in a phase III randomized, placebocontrolled study. BMT Tandem Meetings (Abstract) (2010)
77. H. Ning, F. Yang, M. Jiang, L. Hu, K. Feng, J. Zhang, Z. Yu, B. Li, C. Xu, Y. Li, J. Wang, J. Hu, X. Lou, H. Chen. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia, 22(3), 593-9 (2008) (Pubitemid 351386730)
78. S. Y. Joo, K. A. Cho, Y. J. Jung, H. S. Kim, S. Y. Park, Y. B. Choi, K. M. Hong, S. Y. Woo, J. Y. Seoh, S. J. Cho, K. H. Ryu. Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner. Cytotherapy, 12(3), 361-70 (2010)
79. M. Sudres, F. Norol, A. Trenado, S. Gregoire, F. Charlotte, B. Levacher, J. J. Lataillade, P. Bourin, X. Holy, J. P. Vernant, D. Klatzmann, J. L. Cohen. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol, 176(12), 7761-7 (2006) (Pubitemid 43849077)
80. C. K. Min, B. G. Kim, G. Park, B. Cho, I. H. Oh. IL-10-Transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation. Bone Marrow Transplant, 39(10), 637-45 (2007) (Pubitemid 46722844)
81. S. T. Mohanty, L. Kottam, A. Gambardella, M. J. Nicklin, L. Coulton, D. Hughes, A. G. Wilson, P. I. Croucher, I. Bellantuono. Alterations in the self-renewal and differentiation ability of bone marrow mesenchymal stem cells in a mouse model of rheumatoid arthritis. Arthritis Res Ther, 12(4), R149 (2010)
82. A. Augello, R. Tasso, S. M. Negrini, R. Cancedda, G. Pennesi. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collageninduced arthritis. Arthritis Rheum, 56(4), 1175-86 (2007) (Pubitemid 46608642)
83. F. Mao, W. R. Xu, H. Qian, W. Zhu, Y. M. Yan, Q. X. Shao, H. X. Xu. Immunosuppressive effects of mesenchymal stem cells in collagen-induced mouse arthritis. Inflamm Res, 59(3), 219-25 (2010)
84. E. Schurgers, H. Kelchtermans, T. Mitera, L. Geboes, P. Matthys. Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis. Arthritis Res Ther, 12(1), R31 (2010)
85. F. Djouad, V. Fritz, F. Apparailly, P. Louis-Plence, C. Bony, J. Sany, C. Jorgensen, D. Noel. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum, 52(5), 1595-603 (2005) (Pubitemid 40663952)
86. F. H. Chen, R. S. Tuan. Mesenchymal stem cells in arthritic diseases. Arthritis Res Ther, 10(5), 223 (2008)
87. B. Chen, J. Hu, L. Liao, Z. Sun, Q. Han, Z. Song, R. C. Zhao. Flk-1+ mesenchymal stem cells aggravate collageninduced arthritis by up-regulating interleukin-6. Clin Exp Immunol, 159(3), 292-302 (2010)
88. J. M. Murphy, D. J. Fink, E. B. Hunziker, F. P. Barry. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum, 48(12), 3464-74 (2003) (Pubitemid 37531912)
89. M. Di Nicola, C. Carlo-Stella, M. Magni, M. Milanesi, P. D. Longoni, P. Matteucci, S. Grisanti, A. M. Gianni. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99(10), 3838-43 (2002) (Pubitemid 34534559)
90. O. Ringden, M. Uzunel, I. Rasmusson, M. Remberger, B. Sundberg, H. Lonnies, H. U. Marschall, A. Dlugosz, A. Szakos, Z. Hassan, B. Omazic, J. Aschan, L. Barkholt, K. Le Blanc. Mesenchymal stem cells for treatment of therapyresistant graft-versus-host disease. Transplantation, 81(10), 1390-7 (2006) (Pubitemid 43847148)
91. P. Kebriaei, L. Isola, E. Bahceci, K. Holland, S. Rowley, J. McGuirk, M. Devetten, J. Jansen, R. Herzig, M. Schuster, R. Monroy, J. Uberti. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graftversus-host disease. Biol Blood Marrow Transplant, 15(7), 804-11 (2009)
92. V. K. Prasad, K. G. Lucas, G. I. Kleiner, J. A. Talano, D. Jacobsohn, G. Broadwater, R. Monroy, J. Kurtzberg. Efficacy and Safety of Ex-vivo Cultured Adult Human Mesenchymal Stem Cells (Prochymal(TM)) in Pediatric Patients with Severe Refractory Acute Graft-Versus-Host Disease in a Compassionate Use study. Biol Blood Marrow Transplant (2010)
93. N. Arima, F. Nakamura, A. Fukunaga, H. Hirata, H. Machida, S. Kouno, H. Ohgushi. Single intra-Arterial injection of mesenchymal stromal cells for treatment of steroidrefractory acute graft-versus-host disease: a pilot study. Cytotherapy, 12(2), 265-8 (2010)